SCHEMBL5412575

SCHEMBL5412575

Cc1c(OC2CCC(N)CC2)ccc2c1cnn2C1CCCCO1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ RXRA P19793 1/20 0.38
▸ RXRB P28702 1/20 0.38
▸ RXRG P48443 1/20 0.38
▸ CYP4F2 P78329 4/20 0.36
▸ CYP4A11 Q02928 4/20 0.36
▸ GAA P10253 1/20 0.33
▸ AXL P30530 4/20 0.32
▸ TYRO3 Q06418 4/20 0.32
▸ MERTK Q12866 4/20 0.32
▸ ATR Q13535 4/20 0.32
▸ MAPKAPK2 P49137 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ GRM7 Q14831 1/20 0.31
▸ ENPP1 P22413 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5412574 1.00 ALDH1A1 (0.38) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL5413157 1.00 ALDH1A1 (0.38) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL5425465 0.89 CYP4F2 (0.36) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL5425470 0.89 CYP4F2 (0.36) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL5425473 0.89 CYP4F2 (0.36) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL5415156 0.87 RXRA (0.36) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL5415159 0.87 RXRA (0.36) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL5407733 0.85 IRAK4 (0.40) RXRARXRBRXRGCYP4F2CYP4A11
SCHEMBL5418738 0.83 LMNA (0.39) ALDH1A1LMNAPOLBRXRARXRB
SCHEMBL5418743 0.83 LMNA (0.39) ALDH1A1LMNAPOLBRXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199147-B2 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-03 — — US disclosed
US-20040138286-A1 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-15 — — US disclosed
EP-1403255-A1 Rho KINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138286-A1 Rho kinase inhibitors ROCK1, ROCK2, ARHGDIA ALDH1A1 3541/4885LMNA 2226/4885POLB 3765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback